Within the overarching theme of """"""""New Approaches to Heterogeneity in Dementia,"""""""" Project 2 has focused on Alzheimer's disease (AD). The insights we gained during the preceding funding period and the ever increasing threat AD poses to public health have motivated us to maintain this focus in the current proposal. We will also continue to utilize genetically engineered mice with neuronal expression of human amyloid precursor proteins (hAPP) and amyloid-p (AP) peptides, because there is substantial evidence for mechanistically informative overlap between these models and the human condition. In our original application, we promised to shed light on the processes by which Ap elicits neuronal deficits. We found that neurons in the dentate gyrus and entorhinal cortex - brain regions affected early and severely by AD - are particularly vulnerable to the Ap-induced depletion of proteins that are critical for learning and memory. Several molecules were identified that may mediate this process. We also identified strategies to prevent Apinduced neuronal deficits in hAPP mice. Our new proposal builds on the most promising findings we obtained during the preceding funding period. Specifically, we discovered that the depletion of calciumdependent proteins and associated memory deficits in hAPP mice are likely caused by spontaneous nonconvulsive epileptiform activity in cortical and hippocampal networks. Memory deficits, depletions of calciumdependent proteins, and abnormal network activity could be prevented in hAPP mice through a genetic manipulation that blocks neuronal overexcitation. Independent lines of evidence suggest that epileptiform activity may also play a pathogenic role in humans with AD. We therefore postulate that aberrant excitatory neuronal activity might play an important causal role in the pathogenesis of Ap-induced cognitive impairments in hAPP mice and in AD. This hypothesis will be tested in three new specific aims.
In Aim 1, we will examine whether markers of abnormal neuronal activity are increased in brains of"""""""" patients with mild cognitive impairment (MCI), AD, or other dementias.
In Aim 2, we will test whether available anti-epileptic drugs can prevent or reverse EEC abnormalities in AD-related mouse models.
In Aim 3, we will test whether any of these anti-epileptic drugs can also prevent or reverse cognitive deficits in these models. Confirmation of these untested hypotheses should help elucidate the mechanisms that underlie Ap-dependent cognitive deficits and pave the way for the development of better treatments for AD. Although there is plenty of ' evidence for a potential role of epilepsy in the development of AD, there appear to have been no rigorous clinical trials of anti-epileptic drugs in patients with MCI or early AD. The experiments described in our application could pave the path towards such a clinical trial and provide critical guidance in the selection of the most promising drugs. The proposed ADRC will provide an ideal environment for us to achieve these goals.

Public Health Relevance

The purpose of this project is to explore whether epileptic activity plays a causal role in the development of Alzheimer's disease (AD). The experiments described in our application could pave the path towards a clinical trial of anti-epileptic drugs in AD and provide critical guidance in the selection of the most promising medications.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG023501-10
Application #
8458093
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$177,498
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21
Barton, Cynthia; Ketelle, Robin; Merrilees, Jennifer et al. (2016) Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci Rep 16:14
Rabinovici, Gil D (2016) Amyloid biomarkers: pushing the limits of early detection. Brain 139:1008-10
Voyle, N; Kim, M; Proitsi, P et al. (2016) Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry 6:e719
Schott, Jonathan M; Crutch, Sebastian J; Carrasquillo, Minerva M et al. (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement 12:862-71
Yokoyama, Jennifer S; Desikan, Rahul S (2016) Association of Alzheimer Disease Susceptibility Variants and Gene Expression in the Human Brain-Reply. JAMA Neurol 73:1255
LoBue, Christian; Denney, David; Hynan, Linda S et al. (2016) Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis. J Alzheimers Dis 51:727-36
Mair, Waltraud; Muntel, Jan; Tepper, Katharina et al. (2016) FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal Chem 88:3704-14
Oh, Hwamee; Madison, Cindee; Baker, Suzanne et al. (2016) Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. Brain 139:2275-89
Guo, Christine C; Sturm, Virginia E; Zhou, Juan et al. (2016) Dominant hemisphere lateralization of cortical parasympathetic control as revealed by frontotemporal dementia. Proc Natl Acad Sci U S A 113:E2430-9

Showing the most recent 10 out of 390 publications